Grujic Alan 4

What Happened

• Alan Grujic, a director of Guided Therapeutics, was granted a derivative equity award for 110,000 shares on March 10, 2026. The reported acquisition price is $0.00 (i.e., an awarded grant rather than an open‑market purchase or sale).

Key Details

• Transaction date: 2026-03-10; Form 4 filed: 2026-04-07 (filed roughly four weeks after the transaction; appears late relative to the typical 2-business-day filing deadline).
• Nature: Award/Grant of derivative securities (reported as "A" on Form 4); 110,000 shares granted at $0.00.
• Vesting: 1/4 of the award (27,500 shares) vested on March 10, 2026; remaining shares vest monthly starting June 10, 2026, subject to continued service, and will be fully vested by March 9, 2029 (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• No indication this was a sale or a purchase of existing stock — it is compensation-related.

Context

• This was a compensation grant to a director (common practice) rather than a market purchase; awards at $0.00 mean no cash was paid by the insider at grant. Vesting ties the award to continued service, so shares become owned over time.
• Such grants are informative about executive/director compensation but do not necessarily signal an immediate buy or sell view on the stock.